Viridian Therapeutics is advancing its pipeline with positive phase 3 results for veligrotug in thyroid eye disease and plans a BLA submission in November 2025. VRDN is expanding its TED program with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results